Proactive Investors - Run By Investors For Investors

CannPal Animal Therapeutics granted medical cannabis permit

The company listed on the ASX in October 2017 after raising $6M.
a dog sitting in a garden
Clinical trials planned for Q1 CY18.

CannPal Animal Therapeutics Ltd (ASX:CP1) has been granted an authorisation to possess and supply cannabis for scientific research by the New South Wales Ministry of Health.

The authorisation has been issued under the provisions of the Drug Misuse and Trafficking Act 1985.

Importantly, the permit allows CannPal to apply for permits to import cannabis for the clinical trials planned for Q1 CY18.

CannPal is a pharmaceutical-focused animal health company researching the benefits of medical cannabis for companion animals.

The company listed on the ASX in October 2017 after raising $6 million at an issue price of $0.20 per share.

CannPal has been working closely with Invetus, Australasia’s largest veterinary research organisation, to facilitate the importation of cannabis for scientific research in companion animals.

CannPal’s agreement with Invetus allows the company to store and research its prohibited substances at a secure purpose-built animal health research facility.

The cannabis oils being imported are for the company’s pharmacokinetic and safety studies scheduled for Q1 CY18.

The University of Queensland will be providing bioanalytical services for the studies with the results anticipated in Q2 CY18.

Join Proactive’s Crypto, Blockchain and Cannabis Telegram group here
View full CP1 profile View Profile

CannPal Animal Therapeutics Ltd Timeline

Related Articles

cannabis extract
January 17 2019
The Kelowna, BC-based cannabis company specializes in the research, development, production, and testing of high-quality cannabis extracts and oils
cannabis bud on tray
April 25 2019
Armed with a new partnership with Canada's largest pharmacy and an international cultivator, Flowr is aiming to provide medicinal and recreational consumers around the world with premium, high-quality cannabis
cannabis tablet
March 01 2019
The company fills a niche in the medicinal cannabis market, as it continues to push forward its suite of precision oral dose products

© Proactive Investors 2019

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use